Global, Regional, and National Prevalence of Gout From 1990 to 2019: Age-Period-Cohort Analysis With Future Burden Prediction

Abstract

Background Gout is a common and debilitating condition that is associated with significant morbidity and mortality. Despite advances in medical treatment, the global burden of gout continues to increase, particularly in high–sociodemographic index (SDI) regions. Objective To address the aforementioned issue, we used age-period-cohort (APC) modeling to analyze global trends in gout incidence and prevalence from 1990 to 2019. Methods Data were extracted from the Global Burden of Disease Study 2019 to assess all-age prevalence and age-standardized prevalence rates, as well as years lived with disability rates, for 204 countries and territories. APC effects were also examined in relation to gout prevalence. Future burden prediction was carried out using the Nordpred APC prediction of future incidence cases and the Bayesian APC model. Results The global gout incidence has increased by 63.44% over the past 2 decades, with a corresponding increase of 51.12% in global years lived with disability. The sex ratio remained consistent at 3:1 (male to female), but the global gout incidence increased in both sexes over time. Notably, the prevalence and incidence of gout were the highest in high-SDI regions (95% uncertainty interval 14.19-20.62), with a growth rate of 94.3%. Gout prevalence increases steadily with age, and the prevalence increases rapidly in high-SDI quantiles for the period effect. Finally, the cohort effect showed that gout prevalence increases steadily, with the risk of morbidity increasing in younger birth cohorts. The prediction model suggests that the gout incidence rate will continue to increase globally. Conclusions Our study provides important insights into the global burden of gout and highlights the need for effective management and prophylaxis of this condition. The APC model used in our analysis provides a novel approach to understanding the complex trends in gout prevalence and incidence, and our findings can inform the development of targeted interventions to address this growing health issue.

Global Trends in the Incidence of Anxiety Disorders From 1990 to 2019: Joinpoint and Age-Period-Cohort Analysis Study

“…In terms of incidence, the ASIR was higher among female individuals than among male individuals in 2019. This was consistent with the results of previous studies [ 11 , 26 ]. In 2015, a systematic review of prevalence studies showed that female individuals were twice as likely as male individuals to have ADs [ 4 ], which indicated that more female individuals are affected by ADs than male individuals worldwide.…”

“…This study predicted the incidence rate of ADs from 2020 to 2044 by running a Nordpred age-period-cohort analysis by sex using the Nordpred package in R (R Foundation for Statistical Computing), accounting for changing rates and changing population structures. This method has been fully demonstrated and recognized in previous studies [ 26 ].…”

Cost-effectiveness of Lung Cancer Screening Combining with CVD and COPD Screening: A Microsimulation Study

“…The highest incidence of CVD was in the age group of 50-70 years old, accounting for about half in all. 40 In addition, although the prevalence of COPD in China is lower than in western countries, its mortality rate is signi cantly higher. 41 Early screening for "big-3 diseases" can slow down disease progression and reduce their mortality.…”

Association between Gout and Gastric Cancer: A Nested Case–Control Study Using a National Health Sample Cohort

“…However, its incidence rate is continuously increasing. According to the Global Burden of Disease Study 2019, the global incidence of gout has increased by 63.44% over the past 20 years, resulting in a 51.12% increase in the number of years lived with a disability [ 3 ]. Gout is associated with various systemic and metabolic diseases, including cardiovascular disease, chronic kidney disease, neurodegenerative diseases, diabetes, osteoporosis, and metabolic syndrome [ 4 ].…”